Skip to main content
. 2017 Dec 6;14(2):314–321. doi: 10.1080/21645515.2017.1395540

Table 1.

Study design characteristics.

Study Year Design Participants Administrating method Dosing groups
Creech17 2017 Prospective,multicentre,randomized, controlled, double-blind Participants receiving SA3Ag or SA4Ag or placebo a single 0.5 mL intramuscular injection into the deltoid muscle SA3Ag, low-dose SA4Ag, mid-dose SA4Ag, high-dose SA4Ag, placebo
Frenck16 2017 Prospective,multicentre,randomized, controlled, double-blind Participants receiving SA4Ag or placebo a single 0.5 mL intramuscular injection into the deltoid muscle Low-dose SA4Ag, mid-dose SA4Ag, high-dose SA4Ag, placebo
Nissen20 2015 Prospective,multicentre,randomized, controlled, double-blind Participants in the two age groups receiving SA3Ag or placebo, independently Not Reported Low-dose SA3Ag, mid-dose SA3Ag, high-dose SA3Ag, placebo

SA3Ag: Staphylococcus aureus three-antigen vaccine; SA4Ag: Staphylococcus aureus four-antigen vaccine.